

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number
WO 2005/085196 A3

(51) International Patent Classification⁷: **C07D 209/48**,
233/66, 471/04, A61K 31/4035, A61P 35/00

(21) International Application Number:
PCT/EP2005/002437

(22) International Filing Date: 8 March 2005 (08.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04005498.3 8 March 2004 (08.03.2004) EP
04014619.3 22 June 2004 (22.06.2004) EP

(71) Applicants (for all designated States except US): **DKFZ**
[DE/DE]; Deutsches Krebsforschungszentrum, Stiftung
des öffentlichen Rechts, Im Neuenheimer Feld 280, 69120
Heidelberg (DE). **INSTITUTE OF BIOCHEMISTRY
AND BIOPHYSICS PAS** [PL/PL]; Pawinskiego 5a,
02-106 Warszawa (PL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GARCIA BOY,**
Regine [DE/DE]; Mönchhofstrasse 54, 69120 Heidelberg
(DE). **LYKO, Frank** [DE/DE]; Albert-Mays-Strasse 3,
69115 Heidelberg (DE). **SIEDLECKI, Pawel** [PL/PL];
Mokotowska 24/4, PL-00-560 Warszawa (PL).

(74) Agent: **HUHN, Michael**; Isenbruck, Bösl, Hörschler,
Wichmann, Huhn, Patentanwälte, Theodor-Heuss-Anlage
12, 68165 Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
8 December 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF DNA METHYLATION IN TUMOR CELLS



(57) **Abstract:** The present invention relates to compounds according to the general formula (I) wherein the dotted lines denote a single bond which is optionally present, with 2 dotted lines denoting a double bond; wherein, in case no double bond is present and a free valence exists, this valence is occupied by H; and wherein the symbols in particular have the following meanings: R¹ and R² are independently from each other selected from the group consisting of: H; OH; (=O); halogens; pseudohalogens; NH₂; S(O)_mR⁵; SO₂NH₂; C(O)R⁸; C(O)OR⁹; CONH₂; C₁-C₂-alkyl substituted by NH₂, OH, S(O)_mR⁵, SO₂NH₂, C(O)R⁸, C(O)OR⁹, CONH₂; C₁-C₂-alkoxy substituted by NH₂, OH, S(O)_mR⁵, SO₂NH₂, C(O)R⁸, C(O)OR⁹, CONH₂; Ar denotes an unsubstituted mononuclear aryl group having 6 or 7 members, which aryl group is annulated to the neighbouring 5-membered cycle, and which may carry 1, 2 or 3 heteroatoms from the group N, O and S in its cycle; Y, Z denote independently from each other a nitrogen atom or a methylene group; X is a nitrogen atom or a methylene group; A is selected from the group consisting of: H; halogens and pseudohalogens; OH; =N(OH); NR¹²R¹³; OSO₃; S(O)_mR¹⁴; SO₂NR¹⁵R¹⁶; C(O)R¹⁷; C(O)OR¹⁸; CONR¹⁹R²⁰; C(S)R²¹; C(S)OR²²; unsubstituted and at least monosubstituted C₁-C₆-alkyl which can carry in its chain one or more non-adjacent heteroatoms from the group nitrogen and oxygen. These compounds are used as inhibitors of DNA methylation and therefore useful in the treatment of various forms of cancer.



WO 2005/085196 A3